Macular Degeneration Trial, Recruiting NCT07085533 Sponsor: Zhongmou Therapeutics Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT07085533
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to verbally identify or describe colors and can understand and follow instructions during color vision testing
  • People who have been formally diagnosed with an inherited retinal dystrophy (a genetic condition affecting the retina) — for the IRD participant group only
  • People who have no known history of inherited retinal disease, have healthy retinas or only eye conditions unrelated to retinal function (such as mild cataracts or a corrected vision prescription), and have normal or expected-normal color vision — for the control group only

Who may not be able to join:

  • People whose color vision difficulties are caused by conditions affecting the optic nerve (such as optic neuritis or glaucoma-related nerve damage), the brain's visual processing areas, or any other neurological condition unrelated to the retina
  • People with severe developmental delays, cognitive impairments that would prevent them from reliably completing color vision tests, or psychiatric conditions that affect visual interpretation or reliable testing
  • People who have recently had retinal surgery, recently used medications that affect retinal structure or function, or had any recent eye intervention that may mean their retinal condition is not yet in a stable state

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yin Shen, Renmin Hospital of Wuhan University

Phone: +86 15527905531

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Zhongmou Therapeutics
Registry
ClinicalTrials.gov
Start date
20 July 2025
Est. completion
4 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Comparison of the Moji Low Vision Color Discrimination Test with other color discrimination tests in detecting participants' color vision ability.; Evaluating the efficiency of Moji LVCDT in participants with extreme Low BCVA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov